New cell and gene therapy CDMO Artis BioSolutions announced its emergence from stealth, alongside its acquisition of CDMO Landmark Bio.
San Diego-based Artis raised an undisclosed amount in a funding round led by venture capital firm Oak HC/FT. Artis intends to use the funds to further build out its services and technology platform and accelerate future growth.
Now part of Artis, Landmark will continue to operate as a distinct entity, focused on accelerating therapeutic development from preclinical through commercialization. Together with Artis, Landmark Bio will enhance its ability to provide integrated, end-to-end solutions, with expanded capabilities in process, analytical and formulation development, GMP manufacturing and QC testing, CMC consulting and IND enabling services, and manufacturing technology development.
Landmark was founded in 2021 by leaders from industry, academia and research hospitals from the greater Boston area. The company unveiled a 44,000 square-foot fully integrated development and manufacturing facility in Watertown, Massachusetts in 2022.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!